Chinese interferon market - Sharp year-on-year decline of 50.4% in interferon revenue (RMB361 million)

Wednesday, April 26, 2017 General News
Email Print This Page Comment
Font : A-A+

NEW YORK, April 25, 2017 /PRNewswire/ -- Interferon is mainly used for the treatment of hepatitis B, hepatitis C, multiple

sclerosis, condyloma acuminatum and other diseases. Wherein, IFN-? is mainly suitable for curing hepatitis B and hepatitis C, while IFN-? is the mainstream medicine for MS which sees a higher incidence in Europe and America
than in Asia, so foreign countries usually adopt IFN-? whereas clinical applications in China center on IFN-?.Read the full report: http://www.reportlinker.com/p04838480/China-Interferon-Industry-Report.htmlChina where liver diseases prevail has maintained the demand for interferon worth more than RMB4 billion in recent years, of which hepatitis B-use interferon accounts for over 60% of the entire interferon market. However, the hepatitis B-use interferon market rapidly shrank in 2016 under the impact of the expired patented drugs, the substitution of nucleoside drugs and other factors, resulting in the sharp year-on-year decline of 50.4% in the interferon revenue (RMB361 million) of Chinese sample hospitals in 2016; it was estimated that Chinese interferon market size hit about RMB2.22 billion in the whole 2016.It is expected that Chinese interferon market will be hard to turn the declining situation around in the next few years. Both of the sluggish hepatitis B-use interferon market and the launch of DAAs drugs will make the hepatitis C-use interferon market suffer a crisis. At present, the overseas hepatitis C-use interferon market has been significantly affected by DAAs drugs and slumped. Although DAAs drugs are not available in China, more than 30 companies have filed for DAAs drugs and DAAs drugs are expected to be revealed in this country within 2 years, which will impact the domestic interferon market once again then.In recent years, Chinese interferon market is mainly occupied by Roche and MSD, which seize more than 60% market share together, while local Chinese peers represented by Anke Biotechnology, Kawin Technology and Tri-Prime Gene grasp no more than 5% apiece. But in 2016, the contracted hepatitis B-use interferon market dramatically dragged down the combined market share of Roche and MSD to about 40%.Interferon is mainly divided into ordinary interferon and long-acting interferon. Compared with ordinary interferon which should be injected three times a week, long-acting interferon is injected only once a week, which significantly reduces the patients' medication compliance with less side effect. Yet, Chinese long-acting interferon market has been monopolized by Roche and MSD which offer high prices.On October 13, 2016, China's first long-acting interferon developed by Amoytop Biotech with independent intellectual property rights obtained the approval for the launch, breaking the monopoly of foreign enterprises. Moreover, Anke Biotechnology, Tri-Prime Gene, Chia Tai Tianqing and other companies are developing long-acting interferon. In the future, the competition in Chinese long-acting interferon market will prick up, which will further squeeze the market share of Roche and MSD.The report mainly covers the following:Overview of China interferon industry, including development process, status quo, market size, market structure and competitive landscape;Analysis on China interferon market segments, especially in-depth analysis on market size, competitive landscape and prices of ordinary interferon and long-acting interferon;Analysis on the downstream market of China interferon industry, including status quo and development trend of hepatitis B, hepatitis C and pediatric markets;Operation and interferon business of 17 domestic and 2 foreign interferon enterprises;Read the full report: http://www.reportlinker.com/p04838480/China-Interferon-Industry-Report.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com __________________________Contact Clare: clare@reportlinker.com US: (339)-368-6001Intl: +1 339-368-6001

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/chinese-interferon-market---sharp-year-on-year-decline-of-504-in-interferon-revenue-rmb361-million-300445779.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook